2014

Analysis of the US Retinal Therapeutics Market

NEW YORK, Jan. 7, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Analysis of the US Retinal Therapeutics Market
http://www.reportlinker.com/p01936265/Analysis-of-the-US-Retinal-Therapeutics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Improvements in Administration and Efficacy Drive Growth

Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management of AMD, DME, and RVO from 2009 to 2017, with 2012 as the base year. Segmentation by disorder is provided. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.

Methodology

•The information contained in this research service was derived from a variety of relevant primary and secondary sources.
•Secondary data sources include company publications (annual reports, US Securities and Exchange Commission (SEC) filings, investor presentations, earnings transcripts, and press releases); US government public sources (clinicaltrials.gov, FDA.gov, Orange Book); pharmaceutical industry databases; and published articles in scientific and medical journals.
•Revenue forecasting is performed using a robust, data-driven, bottom-up, patient-based approach. Marketed drugs and potential new entrants in Phase 3 of development and beyond are individually forecast, and aggregate figures are provided.
•Revenue from off-label usage is not included, but is accounted for in forecast models.

Key Findings

Current Market Landscape
•Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) due to their high efficacy and safety.
•By 2017, Genentech and Regeneron are expected to split the AMD, DME, and RVO segments with their VEGF inhibitors Lucentis and Eylea, respectively.
- In 2017, Lucentis and Eylea are each estimated to produce roughly $Xbillion in revenue.
- Eylea's favorable bi-monthly dosing has enabled Regeneron to be a viable competitor to Genentech's Lucentis. In 2014, Eylea's label will expand to include DME.
•Eylea and Lucentis are comparably priced; however, Avastin is available through compounding pharmacies at an immense discount, which significantly disrupts the branded AMD, DME, and RVO market. X to X% of the AMD, DME, and RVO segments are estimated to be off-label Avastin usage.
•Although new VEGF treatments are highly efficacious, they require intravitreal injections which is an invasive procedure. Thus, dosing frequency is a key determinant of market uptake.
•The AMD, DME, and RVO segments are set for continued growth due to an aging US population, and the DME segment in particular due to an increasing prevalence of diabetes.

Future Competitors
•There are more than 15 compounds in Phase 2 development and beyond.
•If approved, Allergan will have the first once-every-3-months VEGF inhibitor with AGN-150998, expected to launch in 2018 to 2019.
- If Phase 3 data shows comparable efficacy and safety to current VEGF inhibitors, Allergan has the potential to gain X% or more of the market due to its less frequent dosing.
•Ophthotec's platelet-derived growth factor (PDGF) inhibitor Fovista has the potential to become the first add-on therapy to VEGF inhibitors.
- This product has significant market potential due to a complementary rather than competitive add-on therapy strategy.
•New treatments that can be administered orally or topical drops would revolutionize treatment; however, it appears unlikely that any current pipeline medications will have comparable safety and efficacy profiles to current VEGF treatments.

Scope and Segmentation

Geographic Coverage: US
Study Period: 2009–2017
Base Year: 2012
Forecast Period: 2013–2017
Monetary Unit: US Dollars

•This research service evaluates the United States market for pharmaceutical treatments for the following retinal diseases: AMD, DME, and RVO.
•Units are defined as patients. Treated patient numbers, when estimated, are derived from annual sales revenue and annual cost of therapy.
•The price is the annual cost of therapy, and the average annual cost of therapy is based on the average wholesale price (AWP) per drug, as reported in Thomson Reuters Red Book. Hospital or clinic-associated expenses are not included in the cost of therapy.
•Indication-specific annual revenue, as reported, is used when available. Otherwise, estimates are used.

Key Questions This Study Will Answer

Is the market growing, how long will it continue to grow, and at what rate?
Are the existing competitors structured correctly to meet customer needs?
What pipeline candidates have the greatest potential? When are they expected to reach market?
Which treatments are set to dominate the market? How much market share for each competitor?
What is the peak sales potential for AMD, DME, and RVO market?
What the strengths and weaknesses of current and future therapies?

Table Of Contents

1. Executive Summary
2. Market Overview
3. Competitive Playbook
4. Total Retinal Therapeutics Market
• Drivers and Restraints
• Forecasts and Trends
5. Competitive Environment
6. AMD Segment Breakdown
7. DME Segment Breakdown
8. RVO Segment Breakdown
9. Key Companies to Watch
10. The Last Word
11. Appendix

List of Exhibits

• Total Retinal Therapeutics Market: Market Engineering Measurements, US, 2012
• Total Retinal Therapeutics Market: Market Segmentation, US, 2012
• Total Retinal Therapeutics Market: Game-changing Strategies, US, 2013
• Total Retinal Therapeutics Market: Key Market Drivers, US, 2012–2017
• Total Retinal Therapeutics Market: Key Market Restraints, US, 2012–2017
• Total Retinal Therapeutics Market: Market Engineering Measurements, US, 2012
• Total Retinal Therapeutics Market: Revenue Forecast, US, 2009–2017
• Total Retinal Therapeutics Market: Average Wholesale Price per Injection, US, 2009–2017
• Total Retinal Therapeutics Market: Competitive Landscape, US, 2013
• Total Retinal Therapeutics Market: Marketed Product Analysis, US, 2013
• Total Retinal Therapeutics Market: Pipeline Analysis, US, 2013
• Total Retinal Therapeutics Market: Absolute Market Share Trend by Revenue US, 2012 and 2017
• Total Retinal Therapeutics Market: Company Market Share Analysis of Top 4 Participants, US, 2012
• Total Retinal Therapeutics Market: SWOT Analysis, US, 2013
• Total Retinal Therapeutics Market: Timeline of Key Events, US, 2009–2017
• Total Retinal Therapeutics Market: Patent Expirations, US, 2000–2030
• Total Retinal Therapeutics Market, AMD Segment: Comparative Best Corrected Visual Acuity from Baseline for Select Marketed Drugs, US, 2012
• AMD Segment: Market Engineering Measurements, US, 2012
• AMD Segment: Revenue Forecast, US, 2009–2017
• AMD Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• AMD Segment: Penetration Analysis, US, 2009–2017
• DME Segment: Market Engineering Measurements, US, 2012
• DME Segment: Revenue Forecast, US, 2009–2017
• DME Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• DME Segment: Penetration Analysis, US, 2009–2017
• RVO Segment: Market Engineering Measurements, US, 2012
• RVO Segment: Revenue Forecast, US, 2009–2017
• RVO Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• RVO Segment: Penetration Analysis, US, 2009–2017

To order this report: Analysis of the US Retinal Therapeutics Market
http://www.reportlinker.com/p01936265/Analysis-of-the-US-Retinal-Therapeutics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.